{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:35:58Z","timestamp":1787027758137,"version":"build-2736575974"},"reference-count":59,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Ovarian cancer has a dismal prognosis. Standard treatment following surgery relies on platinum-based chemotherapy. However, sizeable percentages of patients are unresponsive. Identification of markers predicting the response to chemotherapy might help select eligible patients and spare non-responding patients from treatment-associated toxicity. Cancer\/testis antigens (CTAs) are expressed by healthy germ cells and malignant cells of diverse histological origin. This expression profile identifies them as attractive targets for cancer immunotherapies. We analyzed the correlations between expression of MAGE-A10 and New York esophageal-1 cancer (NY-ESO-1) CTAs at the protein level and the effectiveness of platinum-based chemotherapy in patients with advanced-stage high-grade serous ovarian carcinoma (HGSOC). MAGE-A10 and NY-ESO-1 protein expression was analyzed by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded samples from 93 patients with advanced-stage HGSOC treated at our institutions between January 1996 and December 2013. The correlation between the expression of these markers and response to platinum-based chemotherapy, evaluated according to RECIST 1.1 criteria and platinum sensitivity, measured as platinum-free interval (PFI), progression free (PFS), and overall survival (OS) was explored. The MAGE-A10 protein expression predicted unresponsiveness to platinum-based chemotherapy (p = 0.005), poor platinum sensitivity (p &lt; 0.001), poor PFS (p &lt; 0.001), and OS (p &lt; 0.001). Multivariate analysis identified MAGE-A10 protein expression as an independent predictor of poor platinum sensitivity (p = 0.005) and shorter OS (p &lt; 0.001). Instead, no correlation was observed between the NY-ESO-1 protein expression and response to platinum-based chemotherapy (p = 0.832), platinum sensitivity (p = 0.168), PFS (p = 0.126), and OS (p = 0.335). The MAGE-A10 protein expression reliably identified advanced-stage HGSOC unresponsive to platinum-based chemotherapy. Targeted immunotherapy could represent an important alternative therapeutic option in these cancers.<\/jats:p>","DOI":"10.3390\/cancers15194697","type":"journal-article","created":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:48:31Z","timestamp":1695552511000},"page":"4697","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-1151","authenticated-orcid":false,"given":"Nata\u0161a","family":"Lisica \u0160iki\u0107","sequence":"first","affiliation":[{"name":"Department of Pathology, Forensic Medicine and Cytology, General Hospital Zadar, 23000 Zadar, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Petri\u0107 Mi\u0161e","sequence":"additional","affiliation":[{"name":"Department of Oncology, Clinical Hospital Center Split, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snje\u017eana","family":"Tomi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology, Forensic Medicine and Cytology, Clinical Hospital Center Split, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-0571","authenticated-orcid":false,"given":"Giulia","family":"Spagnol","sequence":"additional","affiliation":[{"name":"Department of Women and Children\u2019s Health, Clinic of Gynecology and Obstetrics, University of Padua, 35122 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-0198","authenticated-orcid":false,"given":"Luka","family":"Matak","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, General Hospital Zadar, 23000 Zadar, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-9708","authenticated-orcid":false,"given":"Antonio","family":"Jureti\u0107","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital Dubrava, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Spagnoli","sequence":"additional","affiliation":[{"name":"Istituto CNR \u201cTranslational Pharmacology\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,23]]},"reference":[{"key":"ref_1","unstructured":"(2023, March 10). SEER Cancer Statistics Factsheets: Ovary Cancer, Available online: http:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12253-014-9827-1","article-title":"Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer","volume":"21","author":"Vrdoljak","year":"2015","journal-title":"Pathol. Oncol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Paw\u0142owska, A., Rekowska, A., Kury\u0142o, W., Pa\u0144czyszyn, A., Kotarski, J., and Wertel, I. (2023). Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310859"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/(SICI)1097-0215(19961115)68:4<471::AID-IJC12>3.0.CO;2-8","article-title":"Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: An analysis of specific T-cell-receptor gene usage","volume":"68","author":"Juretic","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1104547","DOI":"10.3389\/fonc.2023.1104547","article-title":"Understanding CAR T cell therapy and its role in ovarian cancer and peritoneal carcinomatosis from ovarian cancer","volume":"13","author":"Qian","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(03)00982-3","article-title":"Cancer\/testis tumour-associated antigens: Immunohistochemical detection with monoclonal antibodies","volume":"4","author":"Juretic","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40291-020-00476-5","article-title":"Prognostic Value of Melanoma-Associated Antigen-A (MAGE-A) Gene Expression in Various Human Cancers: A Systematic Review and Meta-analysis of 7428 Patients and 44 Studies","volume":"24","author":"Poojary","year":"2020","journal-title":"Mol. Diagn. Ther."},{"key":"ref_13","first-page":"681","article-title":"The expression of cancer-testis antigen in ovarian cancer and the development of immunotherapy","volume":"12","author":"Zhao","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Daudi, S., Eng, K.H., Mhawech-Fauceglia, P., Morrison, C., Miliotto, A., Beck, A., Matsuzaki, J., Tsuji, T., Groman, A., and Gnjatic, S. (2014). Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104099"},{"key":"ref_15","first-page":"5850","article-title":"Heterogeneous T-cell response to MAGE-A10(254-262): High avidity-specific cytolytic T lymphocytes show superior antitumor activity","volume":"61","author":"Dutoit","year":"2001","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ijc.22309","article-title":"Cancer\/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer","volume":"120","author":"Groeper","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/AOG.0000000000000917","article-title":"Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines from the International Federation of Gynecology and Obstetrics (FIGO)","volume":"126","author":"Prat","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1245\/s10434-010-0964-9","article-title":"Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: An exploratory analysis of the AGO-OVAR (ArbeitsgemeinschaftGynaekologischeOnkologie Ovarian Cancer Study Group)","volume":"17","author":"Wimberger","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.acthis.2014.01.003","article-title":"Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas","volume":"116","author":"Spagnoli","year":"2014","journal-title":"Acta Histochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/ijc.25777","article-title":"MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies","volume":"129","author":"Piscuoglio","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1054\/bjoc.2000.1251","article-title":"NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens","volume":"83","author":"Noppen","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: Strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12967-022-03776-y","article-title":"Platinum-resistance in epithelial ovarian cancer: An interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism","volume":"20","author":"Leung","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.semcancer.2012.02.013","article-title":"EMT as the ultimate survival mechanism of cancer cells","volume":"Volume 22","author":"Tiwari","year":"2012","journal-title":"Semin Cancer biology"},{"key":"ref_31","first-page":"7002","article-title":"The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy","volume":"12","author":"Li","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3171\/PED\/2008\/1\/4\/305","article-title":"Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation","volume":"1","author":"Kasuga","year":"2008","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/neuonc\/noq179","article-title":"miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma","volume":"13","author":"Weeraratne","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00784-013-0936-0","article-title":"Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells","volume":"18","author":"Hartmann","year":"2014","journal-title":"Clin. Oral Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00784-017-2242-8","article-title":"MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer","volume":"22","author":"Hartmann","year":"2018","journal-title":"Clin. Oral Investig."},{"key":"ref_36","first-page":"2778","article-title":"Overexpression of MAGE\/GAGE genes in paclitaxel\/doxorubicin-resistant human cancer cell lines","volume":"9","author":"Duan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10362","DOI":"10.1158\/0008-5472.CAN-10-1341","article-title":"Mage-A cancer\/testis antigens inhibit p53 function by blocking its interaction with chromatin","volume":"70","author":"Marcar","year":"2010","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-10-1820","article-title":"MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin","volume":"17","author":"Nardiello","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","article-title":"Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2\u2032-deoxycytidine","volume":"64","author":"Sigalotti","year":"2004","journal-title":"Cancer Res."},{"key":"ref_40","first-page":"6453","article-title":"Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms","volume":"9","author":"Yakirevich","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12104","DOI":"10.1038\/srep12104","article-title":"Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer","volume":"5","author":"Xu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2017.03.509","article-title":"NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer","volume":"145","author":"Szender","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00404-023-06918-9","article-title":"Comparison end-to-end anastomosis with ostomy after secondary surgical cytoreduction for recurrent high-grade serous ovarian cancer: Observational single-center study","volume":"308","author":"Matak","year":"2023","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Alsalloum, A., Shevchenko, J.A., and Sennikov, S. (2023). The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?. Cancers, 15.","DOI":"10.3390\/cancers15061779"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI65822","article-title":"Eliminating malignant contamination from therapeutic human spermatogonial stem cells","volume":"123","author":"Dovey","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF01246677","article-title":"Structure, chromosomal localization, and expression of 12 genes of the MAGE family","volume":"40","author":"Arden","year":"1994","journal-title":"Immunogenetics"},{"key":"ref_47","first-page":"15","article-title":"Expression of cancer-testis (CT) antigens in placenta","volume":"7","author":"Jungbluth","year":"2007","journal-title":"Cancer Immun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S","article-title":"Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1","volume":"80","author":"Marchand","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0959-8049(02)00479-3","article-title":"Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report","volume":"39","author":"Marchand","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2005.08.375","article-title":"Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells","volume":"23","author":"Bonnet","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e003220","DOI":"10.1136\/jitc-2021-003220","article-title":"Phase I\/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund\u2019s adjuvant (IFA) for resected high-risk melanoma","volume":"9","author":"Patel","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CJI.0000000000000348","article-title":"Re-examination of MAGE-A3 as a T-cell Therapeutic Target","volume":"44","author":"Martin","year":"2021","journal-title":"J. Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: A phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e002716","DOI":"10.1136\/jitc-2021-002716","article-title":"Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab","volume":"9","author":"Kim","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/01.cji.0000211299.29632.8c","article-title":"Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients","volume":"29","author":"Davis","year":"2006","journal-title":"J. Immunother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e003581","DOI":"10.1136\/jitc-2021-003581","article-title":"Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer","volume":"10","author":"Blumenschein","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1369\/0022155417742897","article-title":"Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review","volume":"66","author":"Nieuwland","year":"2018","journal-title":"J. Histochem. Cytochem."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4697\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:56:50Z","timestamp":1760129810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,23]]},"references-count":59,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15194697"],"URL":"https:\/\/doi.org\/10.3390\/cancers15194697","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,23]]}}}